Health and economic benefits of public financing of epilepsy treatment in India: An agent-based simulation model

Epilepsia

Volumn 57, Issue 3, 2016, Pages 464-474

  Megiddo, Itamar ^a,b   Colson, Abigail ^a,b,c   Chisholm, Dan ^d   Dua, Tarun ^d   Nandi, Arindam ^a,e   Laxminarayan, Ramanan ^a,b,c  

^a Center for Disease Dynamics Economics and Policy   (United States)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c PRINCETON UNIVERSITY   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e PUBLIC HEALTH FOUNDATION OF INDIA   (India)

Author keywords

Agent based model; Cost effectiveness; Epilepsy; India; Universal public finance

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ANTICONVULSANT THERAPY; ARTICLE; COST BENEFIT ANALYSIS; DISABILITY; ECONOMIC ASPECT; EPILEPSY; GOVERNMENT; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; INDIA; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SIMULATION; COST OF ILLNESS; ECONOMICS; FINANCIAL MANAGEMENT; INSURANCE; PROCEDURES; SYSTEM ANALYSIS; TREATMENT OUTCOME;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; EPILEPSY; FINANCING, GOVERNMENT; HUMANS; INDIA; INSURANCE BENEFITS; SYSTEMS ANALYSIS; TREATMENT OUTCOME;

EID: 84960465640     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.13294     Document Type: Article

References (40)

1. World Health Organization. Atlas: Epilepsy care in the world. Geneva: World Health Organization; 2005.
2. Schmidt D, Schachter SC,. Drug treatment of epilepsy in adults. BMJ 2014; 348: G254.
3. Chisholm D,. Cost-effectiveness of first-line antiepileptic drug treatments in the developing world: A population-level analysis. Epilepsia 2005; 46: 751-759.
4. Gureje O, Chisholm D, Kola L,. Cost-effectiveness of an essential mental health intervention package in Nigeria. World Psychiatry 2007; 6: 42-48.
5. Chisholm D, Saxena S,. Cost effectiveness of strategies to combat neuropsychiatric conditions in sub-Saharan Africa and South East Asia: Mathematical modelling study. BMJ 2012; 344: E609.
6. Meyer A-C, Dua T, Ma J, et al., Global disparities in the epilepsy treatment gap: A systematic review. Bull World Health Organ 2010; 88: 260-266.
7. Radhakrishnan K, Pandian JD, Santhoshkumar T, et al., Prevalence, Knowledge, Attitude, and Practice of Epilepsy in Kerala, South India. Epilepsia 2000; 41: 1027-1035.
8. Neni SW, Latif AZA, Wong SY, et al., Awareness, knowledge and attitudes towards epilepsy among rural populations in East Coast Peninsular Malaysia: A preliminary exploration. Seizure 2010; 19: 280-290.
9. Mbuba CK, Ngugi AK, Fegan G, et al., Risk factors associated with the epilepsy treatment gap in Kilifi, Kenya: A cross-sectional study. Lancet Neurol 2012; 11: 688-696.
10. Maiga Y, Albakaye M, Diallo LL, et al., Current beliefs and attitudes regarding epilepsy in Mali. Epilepsy Behav 2014; 33: 115-121.
11. Tripathi M, Jain D, Devi M,. Need for a national epilepsy control program. Ann Indian Acad Neurol 2012; 15: 89-93.
12. Dua T, de Boer HM, Prilipko LL, et al., Epilepsy care in the world: Results of an ILAE/IBE/WHO Global Campaign Against Epilepsy survey. Epilepsia 2006; 47: 1225-1231.
13. Mbuba CK, Newton CR,. Packages of care for epilepsy in low- and middle-income countries. PLoS Med 2009; 6: E1000162.
14. Rathore C, Rao MB, Radhakrishnan K,. National epilepsy surgery program: Realistic goals and pragmatic solutions. Neurol India 2014; 62: 124-129.
15. Vos T, Flaxman AD, Naghavi M, et al., Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163-2196.
16. Devi G, Satishchandra P, Gururaj G,. National workshop on public health aspects of epilepsy for senior personnel of state health departments in India. Ann Indian Acad Neurol 1999; 2: 29-30.
17. Sridharan R, Murthy BN,. Prevalence and pattern of epilepsy in India. Epilepsia 1999; 40: 631-636.
18. Rao MB, Radhakrishnan K,. Is epilepsy surgery possible in countries with limited resources? Epilepsia 2000; 41 (Suppl. 4): S31-S34.
19. Ps C,. The need for developing comprehensive epilepsy surgery units in India. Indian J Neurosurg 2012; 1: 1.
20. Radhakrishnan K,. Epilepsy surgery in India. Neurol India 2009; 57: 4-6.
21. Thomas SV, Sarma PS, Alexander M, et al., Economic burden of epilepsy in India. Epilepsia 2001; 42: 1052-1060.
22. Megiddo I, Colson AR, Nandi A, et al., Analysis of the Universal Immunization Programme and introduction of a rotavirus vaccine in India with IndiaSim. Vaccine 2014; 32 (S1): A151-161.
23. Nandi A, Megiddo I, Prabhakaran D, et al., Meeting Abstracts: An agent-based simulation modelling approach to extended cost-effectiveness analysis of health interventions. Lancet 2013; 381 (Suppl.): S96.
24. Nandi A, Colson AR, Verma A, et al., The health and economic benefits of scaling up a home-based neonatal care package in rural India: A modeling analysis. Health Policy Plan 2015 Nov 11 [Epub ahead of print].
25. Verguet S, Laxminarayan R, Jamison DT,. Universal public finance of tuberculosis treatment in India: An extended cost-effectiveness analysis. Health Econ 2014; 24: 318-332.
26. Mbuba CK, Ngugi AK, Newton CR, et al., The epilepsy treatment gap in developing countries: A systematic review of the magnitude, causes, and intervention strategies. Epilepsia 2008; 49: 1491-1503.
27. Verguet S, Murphy S, Anderson B, et al., Public finance of rotavirus vaccination in India and Ethiopia: An extended cost-effectiveness analysis. Vaccine 2013; 31: 4902-4910.
28. WHO. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.
29. Chow J, Darley S, Laxminarayan R,. Cost-effectiveness of disease interventions in India. Washington DC: Resour Futur; 2007.
30. Laxminarayan R, Chow J, Shahid-Salles SA,. Intervention cost-effectiveness: Overview of main messages. In, Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al., (Eds) Disease control priorities in developing countries, Washington, DC: Oxford University Press; 2006: 35-86.
31. National Sample Survey Organisation. National Sample Survey 2004 (60th Round)-Schedule 25-Morbidity and Healthcare. New Delhi: Ministry of Statistics and Programme Implementation (MOSPI); 2004.
32. Menon RN, Radhakrishnan K,. A survey of epilepsy surgery in India. Seizure 2015; 26: 1-4.
33. Gaitatzis A, Carroll K, Majeed A, et al., The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia 2004; 45: 1613-1622.
34. Hasan O, Meltzer DO, Shaykevich SA, et al., Hospital readmission in general medicine patients: A prediction model. J Gen Intern Med 2010; 25: 211-219.
35. Annegers JF, Hauser WA, Elveback LR,. Remission of seizures and relapse in patients with epilepsy. Epilepsia 1979; 20: 729-737.
36. Schiller Y, Najjar Y,. Quantifying the response to antiepileptic drugs: Effect of past treatment history. Neurology 2008; 70: 54-65.
37. Engel J Jr, Wiebe S, French J, et al., Practice parameter: Temporal lobe and localized neocortical resections for epilepsy. Epilepsia 2003; 44: 741-751.
38. Current Index of Medical Specialities India (CIMS). Available at: Http://www.cimsasia.com/. Accessed October 10, 2014.
39. Management Sciences for Health. International Drug Price Indicator Guide. Available at: Http://erc.msh.org/mainpage.cfm?file=1.0.htm&module=DMP&language=English. Accessed October 29, 2014.
40. World Health Organization. WHO | Price multiplier for different coverage levels. Available at: Http://www.who.int/choice/cost-effectiveness/inputs/price-multiplier/en/. Accessed December 19, 2014.